NVS - NOVARTIS AG
165.15
0.970 0.587%
Share volume: 2,120,769
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$164.18
0.97
0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | |
|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | |
| Report Date | 04-23-2024 | 07-18-2024 | |
| Total revenue | 12.120 B | 12.872 B | |
| Cost of revenue | 3.096 B | 3.173 B | |
| Gross profit | 9.024 B | 9.699 B | |
| 7.48% | |||
| Operating expenses | 5.261 B | 5.458 B | |
| Selling general and admin | 2.840 B | 3.091 B | |
| Research and development | 2.421 B | 2.367 B | |
| Total expenses | 9.025 B | 9.133 B | |
| 1.20% | |||
| Operating income | 3.095 B | 3.739 B | |
| Ebit | 3.344 B | 4.012 B | |
| Pretax income | 3.129 B | 3.841 B | |
| 22.75% | |||
| Income tax | 441.000 M | 595.000 M | |
| Net income basic | 2.688 B | 3.246 B | |
| 20.76% | |||
| Net income | 2.688 B | 3.246 B | |
| 20.76% |